GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone240-243-1201
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20,000.00
Profitability
Miscellaneous
Employees50
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) posted its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.01. View GlycoMimetics' Earnings History.
When is GlycoMimetics' next earnings date?
What price target have analysts set for GLYC?
6 brokerages have issued 1-year price targets for GlycoMimetics' shares. Their predictions range from $5.00 to $35.00. On average, they expect GlycoMimetics' stock price to reach $16.00 in the next year. This suggests a possible upside of 242.6% from the stock's current price. View Analyst Price Targets for GlycoMimetics.
What is the consensus analysts' recommendation for GlycoMimetics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.
What are Wall Street analysts saying about GlycoMimetics stock?
Here are some recent quotes from research analysts about GlycoMimetics stock:
- 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (10/9/2019)
- 2. HC Wainwright analysts commented, "We base our $23 price target on probability-adjusted forecasts for uproleselan in AML as well as rivipansel in SCD VOC. We use the net present value of our revenue forecast through 2027, apply a 60% POS for AML and a 70% POS for SCD 4x price/sales multiple for AML, and estimated 2019 year-end net cash of $3.11 per share, to arrive at our price target. Our P/S multiple of 4x is inline with GlycoMimetics’ peers that range between 2-5x." (4/12/2019)
Has GlycoMimetics been receiving favorable news coverage?
Media stories about GLYC stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlycoMimetics earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for GlycoMimetics.
Are investors shorting GlycoMimetics?
GlycoMimetics saw a decrease in short interest in September. As of September 30th, there was short interest totalling 3,880,000 shares, a decrease of 20.7% from the August 30th total of 4,890,000 shares. Based on an average daily volume of 978,400 shares, the short-interest ratio is currently 4.0 days. Currently, 11.6% of the shares of the stock are short sold. View GlycoMimetics' Current Options Chain.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Dova Pharmaceuticals (DOVA), Cara Therapeutics (CARA), Axsome Therapeutics (AXSM), CannTrust (CNTTF), Principia Biopharma (PRNB), Omeros (OMER), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Rhythm Pharmaceuticals (RYTM), Wave Life Sciences (WVE), Organogenesis (ORGO), Emisphere Technologies (EMIS), Kura Oncology (KURA), Revance Therapeutics (RVNC) and Karyopharm Therapeutics (KPTI).
What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Ms. Rachel K. King, Pres, CEO & Director (Age 60)
- Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
- Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
- Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
- Mr. Henry Flanner, VP of Technical Operations
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $4.67.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $201.70 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.
What is GlycoMimetics' official website?
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
